Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival.

Wimmer K, Bolliger M, Bago-Horvath Z, Steger G, Kauer-Dorner D, Helfgott R, Gruber C, Moinfar F, Mittlböck M, Fitzal F.

Ann Surg Oncol. 2019 Dec 23. doi: 10.1245/s10434-019-08089-x. [Epub ahead of print]

PMID:
31873929
2.

Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.

Papakonstantinou A, Matikas A, Bengtsson NO, Malmström P, Hedayati E, Steger G, Untch M, Hübbert L, Johansson H, Hellström M, Gnant M, Loibl S, Greil R, Moebus V, Foukakis T, Bergh J.

Cancer. 2019 Dec 18. doi: 10.1002/cncr.32653. [Epub ahead of print]

PMID:
31851385
3.

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou A, Hedayati E, Hellström M, Johansson H, Gnant M, Steger G, Greil R, Untch M, Moebus V, Loibl S, Foukakis T, Bergh J, Matikas A.

Acta Oncol. 2020 Jan;59(1):75-81. doi: 10.1080/0284186X.2019.1670353. Epub 2019 Oct 4.

PMID:
31583943
4.

HPV8 activates cellular gene expression mainly through Sp1/3 binding sites.

Kirschberg M, Heuser S, Syed AS, Steger G, Majewski S, Hufbauer M, Akgül B.

Virology. 2019 Sep;535:136-143. doi: 10.1016/j.virol.2019.06.019. Epub 2019 Jul 1.

PMID:
31299490
5.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
6.

News from the San Antonio Breast Cancer Symposium 2018.

Pfeiler G, André F, Janni W, Steger G, Untch M.

Breast Care (Basel). 2019 Mar;14(1):60-62. doi: 10.1159/000497371. Epub 2019 Feb 13. No abstract available.

7.

The Protein Tyrosine Phosphatase H1 PTPH1 Supports Proliferation of Keratinocytes and is a Target of the Human Papillomavirus Type 8 E6 Oncogene.

Taute S, Böhnke P, Sprissler J, Buchholz S, Hufbauer M, Akgül B, Steger G.

Cells. 2019 Mar 14;8(3). pii: E244. doi: 10.3390/cells8030244.

8.

Management of HER2-Positive Early Breast Cancer.

Steger G, Lüftner D, Stöger H, Thürlimann B, Untch M.

Breast Care (Basel). 2018 Dec;13(6):453-455. doi: 10.1159/000494945. Epub 2018 Dec 5. No abstract available.

9.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
10.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
11.

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.

Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, Schem C, Steger G, Timotheadou E, Zaman K, Torri V; MACBETH Group.

Cancer Chemother Pharmacol. 2019 Feb;83(2):301-318. doi: 10.1007/s00280-018-3717-2. Epub 2018 Nov 20.

PMID:
30460489
12.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J.

Ann Oncol. 2019 Jan 1;30(1):109-114. doi: 10.1093/annonc/mdy475.

13.

Viroid research and its significance for RNA technology and basic biochemistry.

Steger G, Riesner D.

Nucleic Acids Res. 2018 Nov 16;46(20):10563-10576. doi: 10.1093/nar/gky903. Review.

14.

Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

Miller K, Steger GG, Niepel D, Lüftner D.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9.

15.

Inability of DNAzymes to cleave RNA in vivo is due to limited Mg[Formula: see text] concentration in cells.

Victor J, Steger G, Riesner D.

Eur Biophys J. 2018 May;47(4):333-343. doi: 10.1007/s00249-017-1270-2. Epub 2017 Dec 16.

PMID:
29248953
16.

Induction of Tyrosine Phosphorylation of UV-Activated EGFR by the Beta-Human Papillomavirus Type 8 E6 Leads to Papillomatosis.

Taute S, Pfister HJ, Steger G.

Front Microbiol. 2017 Nov 10;8:2197. doi: 10.3389/fmicb.2017.02197. eCollection 2017.

17.

Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.

Pavo N, Raderer M, Goliasch G, Wurm R, Strunk G, Cho A, Novak JF, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider ST, Parschalk B, Scheithauer W, Pirker R, Kiesewetter B, Pacher R, Zielinski C, Hülsmann M.

Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. eCollection 2017 Oct 6.

18.

Therapeutic approaches for protecting bone health in patients with breast cancer.

Lüftner D, Niepel D, Steger GG.

Breast. 2018 Feb;37:28-35. doi: 10.1016/j.breast.2017.10.007. Epub 2017 Oct 23. Review.

PMID:
29073497
19.

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart MJ, Von Minckwitz G, Baselga J, Loi S.

Eur J Cancer. 2017 Nov;85:133-145. doi: 10.1016/j.ejca.2017.08.020. Epub 2017 Sep 17.

20.

VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.

Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T, Qamra A, Xu C, Myint SS, Davies JOJ, Goh JY, Loh G, Tan BC, Rozen SG, Yu Q, Tan IBH, Cheng CWS, Li S, Chang KTE, Tan PH, Silver DL, Lezhava A, Steger G, Hughes JR, Teh BT, Tan P.

Cancer Discov. 2017 Nov;7(11):1284-1305. doi: 10.1158/2159-8290.CD-17-0375. Epub 2017 Sep 11.

21.

Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.

Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, Ardizzoia A, Blasinska-Morawiec M, Espinosa E, Villanova G.

Clin Breast Cancer. 2018 Feb;18(1):e41-e47. doi: 10.1016/j.clbc.2017.05.012. Epub 2017 Jun 27.

PMID:
28666812
22.

Propagation and some physiological effects of Citrus bark cracking viroid and Apple fruit crinkle viroid in multiple infected hop (Humulus lupulus L.).

Matoušek J, Siglová K, Jakše J, Radišek S, Brass JRJ, Tsushima T, Guček T, Duraisamy GS, Sano T, Steger G.

J Plant Physiol. 2017 Jun;213:166-177. doi: 10.1016/j.jplph.2017.02.014. Epub 2017 Mar 27.

PMID:
28395198
23.

Modelling the three-dimensional structure of the right-terminal domain of pospiviroids.

Steger G.

Sci Rep. 2017 Apr 6;7(1):711. doi: 10.1038/s41598-017-00764-x.

24.

ZNF395 Is an Activator of a Subset of IFN-Stimulated Genes.

Schroeder L, Herwartz C, Jordanovski D, Steger G.

Mediators Inflamm. 2017;2017:1248201. doi: 10.1155/2017/1248201. Epub 2017 Feb 21.

25.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

26.

Viroid quasispecies revealed by deep sequencing.

Brass JR, Owens RA, Matoušek J, Steger G.

RNA Biol. 2017 Mar 4;14(3):317-325. doi: 10.1080/15476286.2016.1272745. Epub 2016 Dec 27.

27.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D.

Ann Oncol. 2017 Apr 1;28(4):754-760. doi: 10.1093/annonc/mdw665.

28.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

29.

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group (ABCSG).

JAMA. 2016 Nov 8;316(18):1888-1896. doi: 10.1001/jama.2016.15865.

PMID:
27825007
30.

Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.

Unseld M, Scheithauer W, Weigl R, Kornek G, Stranzl N, Bianconi D, Brunauer G, Steger G, Zielinski CC, Prager GW.

J Gastrointest Oncol. 2016 Aug;7(4):588-94. doi: 10.21037/jgo.2016.05.01.

31.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators.

Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5.

PMID:
27501767
32.

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Cancer Med. 2016 Sep;5(9):2350-8. doi: 10.1002/cam4.827. Epub 2016 Jul 25.

33.

Pathological complete remission and long-term outcome-what do we know in 2016?

Gnant M, Steger GG, Bartsch R.

Lancet Oncol. 2016 Jun;17(6):693-694. doi: 10.1016/S1470-2045(16)30038-9. Epub 2016 May 11. No abstract available.

PMID:
27179401
34.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

35.

NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an In Vitro Model of Colonic Carcinoma.

Körber MI, Staribacher A, Ratzenböck I, Steger G, Mader RM.

Anticancer Res. 2016 Apr;36(4):1631-9.

PMID:
27069140
36.

Structure and Associated Biological Functions of Viroids.

Steger G, Perreault JP.

Adv Virus Res. 2016;94:141-72. doi: 10.1016/bs.aivir.2015.11.002. Epub 2016 Mar 2. Review.

PMID:
26997592
37.

Palbociclib for the treatment of postmenopausal breast cancer - an update.

Steger GG, Gnant M, Bartsch R.

Expert Opin Pharmacother. 2016;17(2):255-63. doi: 10.1517/14656566.2016.1133590. Epub 2016 Jan 14. Review.

PMID:
26679057
38.

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.

Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG).

EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug.

39.

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R.

Heart. 2015 Dec;101(23):1874-80. doi: 10.1136/heartjnl-2015-307848. Epub 2015 Sep 28.

PMID:
26416836
40.

Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z.

Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28.

PMID:
26315712
41.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.

PMID:
26303828
42.

Bevacizumab: no comeback in early breast cancer?

Bartsch R, Gnant M, Steger GG.

Lancet Oncol. 2015 Sep;16(9):1001-1003. doi: 10.1016/S1470-2045(15)00124-2. Epub 2015 Aug 10. No abstract available.

PMID:
26272771
43.

The Transcription Factor ZNF395 Is Required for the Maximal Hypoxic Induction of Proinflammatory Cytokines in U87-MG Cells.

Herwartz C, Castillo-Juárez P, Schröder L, Barron BL, Steger G.

Mediators Inflamm. 2015;2015:804264. doi: 10.1155/2015/804264. Epub 2015 Jul 1.

44.

Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.

Promberger R, Dubsky P, Mittlböck M, Ott J, Singer C, Seemann R, Exner R, Panhofer P, Steger G, Bergen E, Gnant M, Jakesz R, Bago-Horvath Z, Rudas M, Bartsch R.

Clin Breast Cancer. 2015 Dec;15(6):505-11. doi: 10.1016/j.clbc.2015.06.007. Epub 2015 Jun 18.

PMID:
26195436
45.

Expression of SANT/HTH Myb mRNA, a plant morphogenesis-regulating transcription factor, changes due to viroid infection.

Matoušek J, Piernikarczyk RJ, Týcová A, Duraisamy GS, Kocábek T, Steger G.

J Plant Physiol. 2015 Jul 1;183:85-94. doi: 10.1016/j.jplph.2015.06.001. Epub 2015 Jun 9.

PMID:
26118459
46.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
47.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A.

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

PMID:
25976743
48.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

49.

plantDARIO: web based quantitative and qualitative analysis of small RNA-seq data in plants.

Patra D, Fasold M, Langenberger D, Steger G, Grosse I, Stadler PF.

Front Plant Sci. 2014 Dec 23;5:708. doi: 10.3389/fpls.2014.00708. eCollection 2014.

50.

CDK4/6 inhibitors in luminal breast cancer.

Gnant M, Steger GG, Bartsch R.

Lancet Oncol. 2015 Jan;16(1):2-3. doi: 10.1016/S1470-2045(14)71188-X. Epub 2014 Dec 16. No abstract available.

PMID:
25524801

Supplemental Content

Loading ...
Support Center